TP53status predicts long-term survival in locally advanced breast cancer after primary chemotherapy
Author:
Publisher
Informa UK Limited
Subject
Radiology, Nuclear Medicine and imaging,Oncology,Hematology,General Medicine
Link
http://www.tandfonline.com/doi/pdf/10.3109/0284186X.2014.922215
Reference28 articles.
1. CARCINOMA OF THE BREAST*
2. Prognosis in inoperable Stage III carcinoma of the breast
3. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy
4. Stage III and localized stage IV breast cancer: Irradiation alone vs irradiation plus surgery
Cited by 14 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Germline TP53 pathogenic variants and breast cancer: A narrative review;Cancer Treatment Reviews;2023-03
2. Targeted gene next‐generation sequencing reveals genomic profile in a cohort of 46 Chinese patients with breast cancer;The Journal of Gene Medicine;2022-05-06
3. Significant impact of circulating tumour DNA mutations on survival in metastatic breast cancer patients;Scientific Reports;2021-03-24
4. Mutant p53 Gain-of-Function: Role in Cancer Development, Progression, and Therapeutic Approaches;Frontiers in Cell and Developmental Biology;2021-02-11
5. TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines;Trends in Cancer;2020-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3